Milestones
2007
Jan |
AsiaPharm buys Nanjing based pharmaceutical group specializing in Oncology for RMB 345.0 million, enhancing its Oncology drug portfolio and accelerating its penetration into the PRC oncology drug sector
AsiaPharm appoints exclusive Korean development agency for proprietary oncology drug CMNa®; underlining its global market penetration initiative |
Feb |
AsiaPharm's proprietary drug Ximingting endorsed by key medical institutions for its effectiveness in treating menopausal symtoms in extensive clinical trials
AsiaPharm seals agreement to sell proprietary pharmaceutical products to Pakistan, further expanding its regional market presence |
2006
May |
AsiaPharm places 80 million new ordinary shares to strategic investors, boosting corporate profile and raising funds of RMB 322.0 million for future expansion
AsiaPharm launches New Formulation Otong - an external use pain relief natural drug, which has significant potential for integration and marketing within OTC drug portfolio
AsiaPharm acquires minority interests of trading subsidiary - Luye Drug Trading - in strategic alignment exercise to focus on higher-margin businesses |
June |
AsiaPharm receives new drug approval for Sailimai - a new formulation for treating acute and chronic diarrhoea |
Oct |
AsiaPharm receives new drug approval for Pantoprazole Sodium Enteric-coated Pellet Capsule, a new oral formulation for the treatment of Chronic Peptic and Gastric ulcers
AsiaPharm acquires proprietary cancer treatment injection drug CMNa® - the only approved chemical sensitizer for radiotherapy in the world, further boosting its Oncology drug portfolio |
2005
11 Jan |
Strategic alliance with Biomedica Foscama of Italy for joint development of drugs
for sale in Asia and Europe. |
07 Feb |
Obtained patent rights for its bi-weekly or monthly sustained-release microspheres
for the injection of Huperzine A drug in the PRC. |
21 Feb |
Obtained State Food and Dug Adminstration approval for clinical trials for
Pantoprazole Sodium delayed-release pellets capsule. |
08 Mar |
Obtained patent rights for Arginine Aescinate for injection, an improved version
of our key product, Maitongna. |
04 Apr |
Exclusive supply agreement with Dr. Reddy’s Laboratories Limited of India to
import FDA/EMEA-approved Pantoprazole Sodium API into the PRC. |
26 May |
Alliance agreement with Napo Pharmaceuticals Inc. of United States for exclusive
rights to develop, market and distribute Crofelemer derived products in PRC. |
27 June |
Collaborative agreement with Sochinaz SA of Switzerland for the exclusive supply
of key ingredient MT103-I for a new drug under development. |
29 Sep |
Obtained State Food and Dug Adminstration approval for clinical trials of
proprietary drugs Huperzine A Fast Disintegrating Tablets and Huperzine A
Sustained-release Tablets. |
13 Oct |
Entered Vietnamese market through appointed distributors. |
14 Nov |
Memorandum of Understanding with Global Harvest Pharmaceutical Ltd. (“GHP”)
of United States, to assist and appoint Asiapharm as qualifi ed pharmaceutical
manufacturer under international regulatory standards. |
28 Nov |
Obtained State Food and Dug Adminstration approval for clinical trials of
Lutingnuo® capsules. |
13 Dec |
Announced the expected launch of Ximingting® in FY2006, a natural proprietary
drug used as an alternative to Hormone Replacement Therapy in the treatment of
menopausal symptoms. |
2004
Launches Initial Public Offer (IPO) at 28cents per share.
Temasek companies Aranda Investments and Seletar Investments received
20 million placement shares, about 19 per cent of AsiaPharm's total
invitation of 105 million share and 4.9 per cent of its enlarged
share capital.
2003
Obtained GMP certification for our production line and manufacturing
process for gel and raw material, Sodium Aescinate. Launched Lutingnuo
(Reduced Glutathione for Injection), principally used for the treatment
of liver ailments.
2002
Launched Olai (Compound Sodium Aescinate Gel), manufactured from
the natural ingredient Sodium Aescinate. Obtained patent for the
composition with low toxicity for anti-inflammation and anti-exudation
of Sodium Aescinate from US Patent and Trademark Office for 20 years.
2001
Nominated by the Ministry of Science and Technology as a production
base to industrialise the results of the National High Tech Research
and Development Programme (“State 863 Programme”).
2000
Obtained GMP certification for our production line and manufacturing
process for tablets, capsules and granules. Our R&D Centre was
recognised by the Shandong Science and Technology Committee as a
“Shandong Natural Drug Engineering Research and Development
Centre”. Obtained GMP certification for our lyophilized powder
injection production line and manufacturing process.
1999
Successfully launched Nuosen (Sodium Pantoprazole for Injection),
a newly formulated prescription drug used for the treatment of gastroenterological
ailments, throughout the PRC. Granted a “Post-doctorate Scientific
Research Work-station” by the State Personnel Ministry.
1998
Established our Research and Development Centre to focus on R&D
to develop new natural active ingredients and drugs with new formulations.
1997
Incorporated Luye Drugs Trading to distribute the products of other
pharmaceutical manufacturers in the PRC.
1995
Commenced production of the natural active ingredient Sodium Aescinate
and our main natural drug, Sodium Aescinate for Injection (Maitongna).
1994
Established Yantai Luye Pharmaceutical Co., Ltd. to engage in the
manufacture and sale of pharmaceutical drugs and active ingredients.
|
